Core Viewpoint - Heptagon Pharmaceuticals (02142) has announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Group 1: Collaboration Details - The collaboration will see AstraZeneca nominate R&D projects to Heptagon Pharmaceuticals annually over the next four years, highlighting the deepening partnership [1] - Heptagon Pharmaceuticals will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms of this collaboration align with the financial framework established in March 2025 [1] Group 2: Market Reaction - Heptagon Pharmaceuticals' stock rose nearly 4% in the afternoon session, with a current increase of 3.15%, trading at HKD 13.76, and a transaction volume of HKD 33.4244 million [1]
和铂医药-B午后涨近4% 公司与阿斯利康深化推进全球战略合作